Literature DB >> 2295790

IL-5 up-regulates but IL-4 down-regulates IL-2R expression on a cloned B lymphoma line.

T Yoshimoto1, K Nakanishi, K Matsui, S Hirose, K Hiroishi, T Tanaka, T Hada, T Hamaoka, K Higashino.   

Abstract

Both IL-4 and IL-5 demonstrate B cell growth activity. IL-5 can render a cloned neoplastic B cell line, BCL1-CL-3 cells, responsive to IL-2, whereas IL-4 has no such activity. The response to IL-5 and IL-2 proceeds in two phases: the first phase which clearly depends upon IL-5 is the obvious increase in number of high affinity IL-2R (3.1-fold) with modest increase of low affinity IL-2R (1.2-fold) and gain of the ability of facilitated IL-2-binding and internalization of IL-2, and the second phase which is induced by IL-2 in the IL-5-stimulated CL-3 cells comprises the striking increase of low affinity IL-2R (8.5-fold). Kinetic study has revealed that high affinity IL-2R expressed on CL-3 cells begins to increase at 6 h and reaches to maximum at 12 h after stimulation with IL-5 or IL-5 plus IL-2, whereas low affinity IL-2R expression increases at 18 h and becomes maximal at 24 h after stimulation of CL-3 cells with IL-5 and IL-2. However, in the presence of IL-4, IL-5 cannot induce an increase in number of high affinity IL-2R on CL-3 cells. Thus, CL-3 cells stimulated with the mixture of IL-5 and IL-4 cannot respond to IL-2, and fail to show up-regulated expression of low affinity IL-2R. IL-4 also has a capacity to modestly interfere with the action of IL-2 to up-regulate low affinity IL-2R expression on IL-5-pretreated CL-3 cells. Thus, this monoclonal B cell system provides an excellent model system to define the roles of IL-5 and IL-4 involved in the B cell differentiation and to characterize the properties of B cells competent to IL-2 stimulation and the signal transduction mechanism which operates through IL-2/IL-2R system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295790

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease.

Authors:  S M Hsu; S S Xie; P L Hsu; J A Waldron
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

2.  IL-4 and transforming growth factor-beta suppress human immunoglobulin secretion in vitro by surface IgD- B cells.

Authors:  C Ninomiya; H L Spiegelberg
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

3.  Expression of IL-2 receptor p55 and p75 chains by human B lymphocytes: effects of activation and differentiation.

Authors:  H Zola; H Weedon; G R Thompson; M C Fung; E Ingley; A J Hapel
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

4.  Human eosinophils express functional interleukin 2 receptors.

Authors:  T H Rand; D S Silberstein; H Kornfeld; P F Weller
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

5.  Flow cytometric studies of IL-4-stimulated expression of the CD25 antigen by quiescent human B lymphocyte subpopulations.

Authors:  R D Butcher; W Cushley
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

6.  Role and regulation of interleukin (IL)-2 receptor alpha and beta chains in IL-2-driven B-cell growth.

Authors:  K Nakanishi; S Hirose; T Yoshimoto; H Ishizashi; K Hiroishi; T Tanaka; T Kono; M Miyasaka; T Taniguchi; K Higashino
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

7.  Interleukin-2 inhibits the interleukin-4-induced human IgE and IgG4 secretion in vivo.

Authors:  H L Spiegelberg; R J Falkoff; R D O'Connor; L Beck
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

8.  Clonal and functional analysis for the augmentation of tumour-infiltrating lymphocytes by interleukin 4.

Authors:  T Tsunoda; H Tanimura; H Yamaue; M Iwahashi; M Tani; K Noguchi; T Hotta; S Mizobata; K Arii
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.